Gonadorelin (also called Factrel) is a synthetic form of gonadotropin-releasing hormone (GnRH) — the brain signal that triggers sex hormone production — used clinically to diagnose and manage disorders of the hypothalamic-pituitary-gonadal axis, including central precocious puberty and certain hormone-sensitive cancers.
What it does
The hypothalamic-pituitary-gonadal (HPG) axis is the hormonal chain of command that governs puberty and sex hormone production. It starts in the hypothalamus, which releases GnRH in pulses; those pulses tell the pituitary gland to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn drive estrogen and testosterone production in the gonads. Gonadorelin is a synthetic copy of that GnRH signal.
How it's used depends entirely on the dosing pattern. Short, pulsatile doses mimic the body's natural rhythm and stimulate LH and FSH release — which is the basis for the GnRH stimulation test used to diagnose central precocious puberty (CPP), a condition where the HPG axis activates too early PubMed 39163851. Continuous, non-pulsatile exposure does the opposite: it desensitizes the pituitary receptors and effectively suppresses sex hormone production. This suppressive effect is what GnRH analogues exploit in treating hormone-sensitive prostate cancer and CPP itself NCT04356430.
In the diagnostic context, a single injection of gonadorelin is given and blood LH levels are measured afterward. A robust LH spike — particularly an elevated LH-to-FSH ratio — confirms that the HPG axis is active PubMed 39163851. Recent research has explored whether pituitary volume measured by MRI can supplement or eventually replace this test, since the stimulation test is invasive PubMed 41669417.
What the evidence shows
Diagnosing central precocious puberty (CPP) Moderate human evidence; well-established clinical standard, but test interpretation is actively being refined
The GnRH stimulation test — giving gonadorelin and measuring the LH response — has been the standard diagnostic tool for HPG axis activation in children for decades. A 2024 study found that averaging peak LH values across multiple time points during the test improved diagnostic accuracy PubMed 39163851. Newer research is comparing gonadorelin against longer-acting GnRH analogues like triptorelin for the same diagnostic purpose; triptorelin produced a stronger and more sustained LH peak in girls with suspected CPP, which some clinicians argue makes interpretation easier PubMed 38712492 PubMed 41384863.
Researchers are also investigating whether the test could eventually be supplemented with biomarkers or imaging. A 593-child cohort study found that 3D MRI-derived pituitary volume correlated moderately with peak LH (r=0.543) and LH/FSH ratio (r=0.480), suggesting imaging may add diagnostic value — though it's not a replacement yet PubMed 41669417. Kisspeptin, a hormone upstream of GnRH, is being studied as an alternative stimulation agent and monitoring tool PubMed 39847034 PubMed 39834030 PubMed 38772409.
Hormone suppression in prostate cancer (via GnRH analogues) Strong human evidence for GnRH agonist/antagonist class; gonadorelin itself is the prototype, but longer-acting analogues dominate clinical practice
Continuous GnRH signaling desensitizes pituitary receptors and drives testosterone to castrate levels — a well-documented mechanism exploited in androgen deprivation therapy (ADT) for prostate cancer. Clinical trials using GnRH-based ADT as neoadjuvant therapy (treatment given before surgery or radiation) for high-risk prostate cancer are ongoing NCT04356430. Comparator trials between GnRH antagonists like abarelix and GnRH agonists like goserelin have evaluated efficacy and side effect profiles in advanced disease NCT00841113. Gonadorelin itself is the foundational molecule; in practice, depot formulations of analogues such as leuprolide or goserelin are used because they require far less frequent dosing.
Treatment of central precocious puberty Strong human evidence for the GnRH agonist class; long-term follow-up data available
Continuous GnRH agonist therapy suppresses premature puberty by downregulating pituitary GnRH receptors. A long-term follow-up trial of triptorelin pamoate in children with CPP has tracked outcomes through adulthood, confirming that treatment delays puberty progression and allows for more typical growth trajectories NCT00909844. Serum bile acid profiling and kisspeptin levels are being explored as additional tools to monitor treatment response in girls undergoing GnRH-based therapy PubMed 40705226 PubMed 38772409.
How it's used
In studies and clinical protocols, dosing varies substantially by indication. For diagnostic GnRH stimulation testing, a single intravenous or subcutaneous bolus of 100 mcg is the conventional approach, with blood drawn at intervals (typically 30–60 minutes post-injection) to measure the LH response PubMed 39163851. For therapeutic suppression of the HPG axis in conditions like CPP or prostate cancer, continuous or depot formulations of longer-acting GnRH analogues — not gonadorelin itself — are standard because the short half-life of native GnRH makes it impractical for ongoing use. Route is typically IV or subcutaneous injection; oral bioavailability is negligible. Specific dosing must be determined by a licensed clinician based on indication, age, weight, and lab findings.
Side effects and safety
In the diagnostic single-dose context, gonadorelin is generally well tolerated. Reported mild effects include injection site reactions, headache, nausea, and transient hot flashes. With ongoing or continuous GnRH-based therapy (relevant to analogues used therapeutically), more significant effects emerge: mood changes, decreased libido, fatigue, and bone density loss — the last of which can progress to clinically significant osteoporosis with long-term use. Cardiovascular events have been documented with prolonged androgen deprivation in men. Gonadorelin is absolutely contraindicated in pregnancy and in active hormone-sensitive malignancies where stimulation — rather than suppression — would be dangerous. Relative contraindications include cardiovascular disease, history of thromboembolism, and pre-existing osteoporosis. Long-term safety data specific to gonadorelin (as opposed to its longer-acting analogues) are limited, since it is rarely used continuously in practice.
Bottom line
Gonadorelin is a well-understood molecule with a decades-long clinical track record, primarily as a diagnostic tool for HPG axis disorders and as the prototype for a widely used class of hormone-suppression therapies. The evidence base for the GnRH stimulation test and GnRH-based ADT is solid, though ongoing research is refining diagnostic criteria and exploring complementary biomarkers. It is a prescription agent with meaningful side effects at therapeutic doses — not a self-administration candidate.